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Hereditary Coproporphyria: Report of an Irish kindred and
identification of a novel gene mutation
Sir,
The case of acute coproporphyria in a 13 years old female, who presented with neuropsychiatric symptoms (visual
hallucinations and peripheral neuropathy) and abdominal pain has previously been described1. We report an Irish kindred
of 8 additional patients with previously undiagnosed hereditary coproporphyria, who were defined following studies of
the family of the index case.
Case Report
The first step in the investigation of suspected acute porphyria is measurement of urinary s-aminolaevulic acid (ALA)
and porphobilinogen (PBG). When raised, acute porphyria is suggested. These tests do not discriminate between the
various types of porphyria, and they return to normal limits within 7-10 days of onset of symptoms. Genetic analysis
subsequently confirmed a previously undiagnosed mutation of the coproporphyrinogen oxidase gene (c.995G>A, R332 Q) at
a locus associated with hereditary coproporphyria.
The treatment of mild episodes of acute porphyria involves highenergy intake, with oral or intravenous glucose. For
more severe cases, haem arginate (Normosangfi, Leiras Medica, Finland) should be infused through a large bore cannula.
This treatment should be instituted early, as it can prevent the development of neurological effects, but it cannot
reverse established neurological effects. Both treatments induce clinical and biochemical remission by reducing ALA
synthesis. Urine ALA and PBG results return rapidly to normal after treatment is commenced2.
As the inheritance of coproporphyria is autosomal dominant, the extended family was invited for screening; 10
accepted, of whom 8 have porphyria. The affected individuals span 3 generations. The youngest diagnosed individual was
3 years old. Following successful family screening, affected family members were educated and counselled, and relevant
hospital and community medical services were informed about these family members. Education included provision of
lists of medications that are thought to be safe and unsafe for individuals with porphyria3, and family planning advice
for female patients. In porphyria, barrier methods of contraception are recommended, as hormonal methods are
recognised precipitants of acute porphyria.
Figure 1 Family tree. Yellow indicates
hereditary coproporphyria on screening and
genetic testing. Blue indicates
noncoproporphyria. The arrow indicates the
index case.
Symptoms possibly attributable to porphyria have since been recognised in 2 of these family members. Shortly after
starting the oral contraceptive pill (a known precipitant of porphyria), a 23 years old female developed abdominal
pain, without associated neuropsychiatric symptoms. This episode resolved following discontinuation of the likely
offending medication and she has been well since. A second female, aged 16 years, required hospital admission with
abdominal pain, without associated neurological or psychiatric symptoms. This episode resolved after instituting a
course of haem arginate. Urinary ALA and PBG subsequently confirmed acute porphyria in both.
Including the index case, 5 patients in the paediatric age range have been diagnosed with porphyria, 2 have had
episodes of acute porphyria. Due to the falling age of menarche3 (menarche is a recognised precipitant of porphyria) we
suggest that more patients with acute porphyria can be expected to present to paediatricians.
Family screening and diagnosis allowed timely medical treatment of 2 episodes of acute porphyria in these kindred.
Thus unnecessary, expensive, prolonged investigations and hospital admission were prevented, and treatment was started
before the patientsâ developed any neurological effects. Family screening should be part of the routine management
of any individual diagnosed with porphyria.
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